Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jerry Olson who wrote (80027)	1/21/2000 2:33:00 PM
From: lee kramer	Read Replies (1) \| Respond to of 120523

OJ: GENE was also a Jenna watch-list placement. My AMZN short is falling faster than the apple toward Newton's noggin. (Lee)

To: Jerry Olson who wrote (80027)	1/21/2000 2:59:00 PM
From: Burjis S.	Read Replies (1) \| Respond to of 120523

Hi Jer, MKTY here is one you should be jumping on. This one was brought to my attention from one very astute trader who has been following this stock for a while she had me buy GWRX at 8.06 and now this one, her reasoning is as follows:MKTY - Mechanical Technology Inc. holds 32 percent stake in PLUG and a 16 percent stake in SatCon Technology Corp., a developer of fuel- cell equipment. Mechanical, which makes sensing instruments for aircraft engines. 32% of PLUG = 1.47B 16% of SATC = 36 million MKTY has just 10.8 million shares outstanding and a market cap of about 567 million...just a little undervalued! Stocks of fuel-cell makers soared in recent days after reports predicted the industry will grow rapidly as customers seek less-polluting energy sources. The cells use hydrogen to produce electricity, emitting only water vapor and are expected to use much less fuel than the engines that now power cars. Also a good Biotech play is going to be BPUR.CAMBRIDGE, Mass., Jan 12, 2000 /PRNewswire via COMTEX/ -- Biopure(R) Corporation (Nasdaq: BPUR) today announced that the company's pivotal Phase III clinical trial of its investigational oxygen therapeutic, Hemopure(R) [hemoglobin glutamer - 250 (bovine)], is continuing to enroll patients following an independent panel's review of safety data from the halfway point of the trial reached in mid-October 1999. The single-blind, 640-patient trial is evaluating Hemopure as a room temperature stable, universally compatible alternative to red blood cell transfusion in orthopedic surgery at more than 40 clinical trial sites in the United States, Canada, Europe and South Africa. Biopure's ongoing Phase III clinical trial allows the administration of up to 10 units of Hemopure perioperatively over the course of six days, with a routine check-up 42 days after surgery. Each unit of product contains approximately 30 grams of purified, chemically cross-linked hemoglobin in 250 milliliters of a balanced salt solution. In this study, serious adverse events reported in the Hemopure group must be no worse than those reported in the group of patients receiving allogeneic red blood cells. Sorry for the lenghty post but the BPUR Stage III trials are also taking place at my hospital and if it goes through, with all this scare about HIV tainted blood, the potential for BPUR is going to be humongous. Best wishes as always, Burj